Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects

por María Gion, José Manuel Pérez-García, Antonio Llombart-Cussac, Miguel Sampayo-Cordero, Javier Cortés, Andrea Malfettone
Publicado 2021

Lymphopenia in hospitalized patients and its relationship with severity of illness and mortality.

por Juan Carlos Andreu-Ballester, Aurelio Pons-Castillo, Antonio González-Sánchez, Antonio Llombart-Cussac, María José Cano, Carmen Cuéllar
Publicado 2021

Nobody dares stopping clinical research, not even COVID-19

por Andrea Malfettone, Serena Di Cosimo, José Manuel Pérez-García, Alicia García, Miguel Sampayo-Cordero, Leonardo Mina, Carolina Herrero, Antonio Llombart-Cussac, Javier Cortés
Publicado 2021

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

por Tomás Pascual, Mafalda Oliveira, Patricia Villagrasa, Vanesa Ortega, Laia Paré, Begoña Bermejo, Serafín Morales, Kepa Amillano, Rafael López, Patricia Galván, Jordi Canes, Fernando Salvador, Paolo Nuciforo, Isabel T. Rubio, Antonio Llombart-Cussac, Serena Di Cosimo, José Baselga, Nadia Harbeck, Aleix Prat, Javier Cortés
Publicado 2021

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

por Fara Brasó-Maristany, Gaia Griguolo, Tomás Pascual, Laia Paré, Paolo Nuciforo, Antonio Llombart-Cussac, Begoña Bermejo, Mafalda Oliveira, Serafín Morales, Noelia Martínez, Maria Vidal, Barbara Adamo, Olga Martínez, Sonia Pernas, Rafael López, Montserrat Muñoz, Núria Chic, Patricia Galván, Isabel Garau, Luis Manso, Jesús Alarcón, Eduardo Martínez, Sara Gregorio, Roger R. Gomis, Patricia Villagrasa, Javier Cortés, Eva Ciruelos, Aleix Prat
Publicado 2020